Between 1988 and 2017, there were significant global variations and trends in ovarian cancer incidence and its subtypes, ...

A phase 1 trial evaluating FSHR-targeting CAR T cells for patients with ovarian cancer has dosed the first patient in its ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

The top 5 ovarian cancer articles of 2024 covered topics such as the impact of air pollution on ovarian cancer risk, treatment strategies for patients with liver metastases, and the benefits of early ...

Susan K. Bohnenkamp, an oncology clinical nurse specialist, is recognized for her compassionate and expert care, going above and beyond to support her patients through their cancer journey. MI ...

FDA officials have set a review date of June 30, 2025, to review avutometinib in combination with defactinib to treat ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade ...